Curanex Pharmaceuticals Inc
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CURX$6.21+7.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| As of March 31, 2026 | As of December 31, 2025 | |
|---|---|---|
| （Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash | $4,018,574 | $4,973,134 |
| Prepaid Expenses | 4,075,144 | 6,254,374 |
| Total current assets | 8,093,718 | 11,227,508 |
| Right-of-Use Asset | 317,574 | 352,616 |
| TOTAL ASSETS | $8,411,292 | $11,580,124 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accrued expenses | $13,240 | $11,915 |
| Accounts payable | 8,404 | 2,426 |
| Lease Liability, current | 107,090 | 122,689 |
| Total current liabilities | 128,734 | 137,030 |
| Lease Liability, noncurrent | 203,910 | 224,010 |
| TOTAL LIABILITIES | 332,644 | 361,040 |
| Shareholders’ equity | ||
| Common stock, 475,000,000 shares authorized; $0.0001 par value; 28,364,812 and 28,340,812 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 2,836 | 2,834 |
| Preferred stock, 25,000,000 shares authorized; $0.0001 par value; 1,000,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 100 | 100 |
| Additional paid-in capital | 16,073,495 | 16,063,705 |
| Accumulated deficit | (7,997,783) | (4,847,555) |
| TOTAL SHAREHOLDERS’ EQUITY | 8,078,648 | 11,219,084 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $8,411,292 | $11,580,124 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.